business

Fujifilm partners with Shanghai firm to seek Chinese COVID-19 approval for Avigan

6 Comments

Japan's Fujifilm Holdings Corp said on Thursday it has partnered with Shanghai-based Carelink Pharmaceutical Co to seek approval in China for Avigan to treat COVID-19 and influenza.

Carelink will use Fujifilm's data on Avigan's treatment of novel coronavirus infections and influenza to seek imported drug approval in China, Fujifilm said in a statement. The two companies also plan to develop an injectable form of the drug.

Fujifilm said last week it was seeking approval for Avigan as a treatment for COVID-19 in Japan. That followed results from a late-stage study in Japan that showed the antiviral drug reduced recovery time for patients with non-severe symptoms.

Avigan, originally developed as an emergency flu drug and known generically worldwide as favipiravir, has been approved in India and Russia to treat COVID-19.

Fujifilm sold global rights in July on Avigan to India's Dr Reddy's Laboratories and Dubai-based Global Response Aid. That deal excluded China, Japan and Russia.

Last month, Fujifilm said the late-stage study of 156 COVID-19 patients in Japan showed that symptoms of those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.

Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant.

© Thomson Reuters 2020.

©2020 GPlusMedia Inc.

6 Comments
Login to comment

Gotta love the two sides of Japan. Govt creates the quad to contain China, and at the same time, the Govt encourages the private sector to court businesses in China. In other words, it’s all about image and money.

8 ( +8 / -0 )

There must’ve a particular reason for that the Japanese large company had to or wanted to corporate Chinese companies with a serious risk of divulging confidential that could lead weaken Japanese technology.

4 ( +4 / -0 )

Last month, Fujifilm said the late-stage study of 156 COVID-19 patients in Japan showed that symptoms of those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.

Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant.

Just 156 patients for a late stage study isn't the sampling too small and if they are so confident of the

effectiveness of the drug why are they not pushing for test to be performed in the U.S and Europe by

recognizable indepedent labs ? Approval in Russia and India and now seeking approval in China doesn't

countries with questionable credibility.

4 ( +4 / -0 )

Gotta love the two sides of Japan. Govt creates the quad to contain China, and at the same time, the Govt encourages the private sector to court businesses in China. In other words, it’s all about image and money.

Japan survives now through becoming over-reliant on different world powers. Abe and Suga have no choice of employing a reliant strategy for the sake of being relevant in the world after the economic miracle collapsed in 1990s and 2008. Relied on China for the industrial exports and tourism/services, relied on Vietnam as a contingency for China, relied on India as a counter against China's military aggression, relied on the USA by default for LDP regime survival alone.

Nowadays, China totally dominates the Japanese industrial-service economy, while the USA takes the finances and equities. Japan has two masters, and they are the Americans and Chinese.

6 ( +6 / -0 )

Great to have two one fails use other n there os no China virus in china bt china still needs the vaccine n medicine for it dont know y

-3 ( +0 / -3 )

Good partnership who else should know better how to treat Chinese virus than Shanghai based company

-1 ( +1 / -2 )

Login to leave a comment

Facebook users

Use your Facebook account to login or register with JapanToday. By doing so, you will also receive an email inviting you to receive our news alerts.

Facebook Connect

Login with your JapanToday account

User registration

Articles, Offers & Useful Resources

A mix of what's trending on our other sites